{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T03:36:49Z","timestamp":1773113809409,"version":"3.50.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":3219,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1093\/annonc\/mdq392","type":"journal-article","created":{"date-parts":[[2010,8,7]],"date-time":"2010-08-07T01:52:57Z","timestamp":1281145977000},"page":"315-320","source":"Crossref","is-referenced-by-count":19,"title":["Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALT trial (phase I\u2013II)"],"prefix":"10.1016","volume":"22","author":[{"given":"M.S.","family":"Rosati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Raimondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Baciarello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Petrelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.L.","family":"Basile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Girolami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Di Seri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Frati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1093\/annonc\/mdq392_bb0010","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ncponc0560","article-title":"The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens","volume":"3","author":"Simon","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdq392_bb0015","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1634\/theoncologist.10-6-370","article-title":"Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy","volume":"10","author":"Norton","year":"2005","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdq392_bb0020","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00002018-200022040-00002","article-title":"Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention","volume":"22","author":"Pai","year":"2000","journal-title":"Drug Saf"},{"key":"10.1093\/annonc\/mdq392_bb0025","first-page":"865","article-title":"Anthracycline cardiomyopathy monitored by morphologic changes","volume":"62","author":"Billingham","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"10.1093\/annonc\/mdq392_bb0030","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djm252","article-title":"HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials","volume":"100","author":"Gennari","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdq392_bb0035","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2009.27.15_suppl.519","article-title":"Anthracyclines in basal breast cancer: the NCIC-CTG trial MA5 comparing adjuvant CMF to CEF","volume":"27","author":"Cheang","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq392_bb0040","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2009.27.15_suppl.523","article-title":"Predicting the efficacy of anthracyclines in breast cancer (BC) patients: results of the neoadjuvant TOP trial","volume":"27","author":"Desmedt","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq392_bb0045","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/sj.bjc.6601634","article-title":"Activity of first line epirubicin and paclitaxel in metastatic breast cancer is independent from type of adjuvant therapy","volume":"90","author":"Gennari","year":"2004","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdq392_bb0050","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/00001813-200606000-00014","volume":"17","author":"Batist","year":"2006","journal-title":"Anticancer Drugs"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdq392_bb0055","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1038\/sj.bjc.6605269","article-title":"Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors","volume":"101","author":"Kelly","year":"2009","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdq392_bb0060","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s12012-007-0014-4","article-title":"Cardiac safety of liposomal anthracyclines","volume":"7","author":"Batist","year":"2007","journal-title":"Cardiovasc Toxicol"},{"issue":"18","key":"10.1093\/annonc\/mdq392_bb0065","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1200\/JCO.2008.19.7939","article-title":"Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial","volume":"27","author":"Dowsett","year":"2009","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1093\/annonc\/mdq392_bb0070","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419386703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419386703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/22\/2\/315\/408332\/mdq392.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T08:48:49Z","timestamp":1624438129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419386703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S0923753419386703"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdq392","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}